Epidermal DNA vaccine for influenza is immunogenic in humans

被引：115

作者：

Drape, Robert J. ^{[1
]}

Macklin, Michael D. ^{[1
]}

Barr, Lori J. ^{[1
]}

Jones, Suzanne ^{[1
]}

Haynes, Joel R. ^{[1
]}

Dean, Hansi J. ^{[1
]}

机构：

[1] PowderJect Vaccines Inc, Middleton, WI 53562 USA

来源：

VACCINE | 2006年 / 24卷 / 21期

关键词：

DNA vaccine; influenza; epidermis; clinical trial;

D O I：

10.1016/j.vaccine.2005.08.012

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

A phase I clinical trial was conducted to evaluate a monovalent influenza DNA vaccine containing the HA gene from A/Panama/2007/99 delivered by particle-mediated epidermal delivery (PMED). Three groups of 12 healthy adult subjects received a single dose on day 0 of either 1, 2 or 4 mu g of DNA vaccine, delivered as 1, 2 or 4 PMED administrations. The PMED influenza DNA vaccine elicited serum hemagglutination-inhibition (HAI) antibody responses at all three dose levels, with the highest and most consistent responses in subjects vaccinated with the highest dose level. Antibody responses were greatest at the last time point tested, day 56. Treatment-related reactions were mild to moderate, and included skin reactions at the vaccine site. These results provide a preliminary indication of the safety and immunogenicity of a prototype epidermal DNA vaccine for influenza. (c) 2005 Elsevier Ltd. All fights reserved.

引用

收藏

页码：4475 / 4481

页数：7

相关论文

共 44 条

[1] Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines [J].

Arrington, J ;

Braun, RP ;

Dong, LC ;

Fuller, DH ;

Macklin, MD ;

Umlauf, SW ;

Wagner, SJ ;

Wu, MS ;

Payne, LG ;

Haynes, JR .

JOURNAL OF VIROLOGY, 2002, 76 (09) :4536-4546

[2] Approaches to improved influenza vaccination [J].

Betts, RF ;

Treanor, JJ .

VACCINE, 2000, 18 (16) :1690-1695

[3] Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy A meta-analysis [J].

Beyer, WEP ;

Palache, AM ;

de Jong, JC ;

Osterhaus, ADME .

VACCINE, 2002, 20 (9-10) :1340-1353

[4] Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza [J].

Chen, Z ;

Sahashi, Y ;

Matsuo, K ;

Asanuma, H ;

Takahashi, H ;

Iwasaki, T ;

Suzuki, Y ;

Aizawa, C ;

Kurata, T ;

Tamura, S .

VACCINE, 1998, 16 (16) :1544-1549

[5] Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs [J].

Chen, Z ;

Matsuo, K ;

Asanuma, H ;

Takahashi, H ;

Iwasaki, T ;

Suzuki, Y ;

Aizawa, C ;

Kurata, T ;

Tamura, S .

VACCINE, 1999, 17 (7-8) :653-659

[6] Protection against influenza B virus infection by immunization with DNA vaccines [J].

Chen, Z ;

Kadowaki, S ;

Hagiwara, Y ;

Yoshikawa, T ;

Sata, T ;

Kurata, T ;

Tamura, S .

VACCINE, 2001, 19 (11-12) :1446-1455

[7] Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein [J].

Chen, Z ;

Yoshikawa, T ;

Kadowaki, S ;

Hagiwara, Y ;

Matsuo, K ;

Asanuma, H ;

Aizawa, C ;

Kurata, T ;

Tamura, S .

JOURNAL OF GENERAL VIROLOGY, 1999, 80 :2559-2564

[8]

CLEMENTS ML, 1984, LANCET, V1, P705

[9] SERUM AND NASAL WASH ANTIBODIES ASSOCIATED WITH RESISTANCE TO EXPERIMENTAL CHALLENGE WITH INFLUENZA-A WILD-TYPE VIRUS [J].

CLEMENTS, ML ;

BETTS, RF ;

TIERNEY, EL ;

MURPHY, BR .

JOURNAL OF CLINICAL MICROBIOLOGY, 1986, 24 (01) :157-160

[10]

Committee for Proprietary Medicinal Products (CPMP), 1997, CPMPBWP21496

← 1 2 3 4 5 →